FULC vs. MELI
Compare and contrast key facts about Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: FULC or MELI.
Key characteristics
| FULC | MELI | |
|---|---|---|
| YTD Return | -50.81% | 19.39% |
| 1Y Return | -20.57% | 30.06% |
| 3Y Return (Ann) | -43.01% | 4.74% |
| 5Y Return (Ann) | -16.16% | 27.89% |
| Sharpe Ratio | -0.17 | 0.85 |
| Sortino Ratio | 0.55 | 1.29 |
| Omega Ratio | 1.09 | 1.19 |
| Calmar Ratio | -0.17 | 0.98 |
| Martin Ratio | -0.40 | 3.24 |
| Ulcer Index | 38.62% | 9.62% |
| Daily Std Dev | 94.01% | 36.66% |
| Max Drawdown | -92.70% | -89.49% |
| Current Drawdown | -89.28% | -12.33% |
Fundamentals
| FULC | MELI | |
|---|---|---|
| Market Cap | $227.14M | $100.25B |
| EPS | -$0.34 | $28.28 |
| Total Revenue (TTM) | $80.87M | $18.43B |
| Gross Profit (TTM) | $79.48M | $8.78B |
| EBITDA (TTM) | -$3.95M | $2.37B |
Correlation
The correlation between FULC and MELI is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
FULC vs. MELI - Performance Comparison
In the year-to-date period, FULC achieves a -50.81% return, which is significantly lower than MELI's 19.39% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
FULC vs. MELI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
FULC vs. MELI - Dividend Comparison
Neither FULC nor MELI has paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
FULC Fulcrum Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MELI MercadoLibre, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.19% | 0.38% | 0.36% | 0.52% | 0.53% |
Drawdowns
FULC vs. MELI - Drawdown Comparison
The maximum FULC drawdown since its inception was -92.70%, roughly equal to the maximum MELI drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for FULC and MELI. For additional features, visit the drawdowns tool.
Volatility
FULC vs. MELI - Volatility Comparison
The current volatility for Fulcrum Therapeutics, Inc. (FULC) is 11.90%, while MercadoLibre, Inc. (MELI) has a volatility of 20.22%. This indicates that FULC experiences smaller price fluctuations and is considered to be less risky than MELI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
FULC vs. MELI - Financials Comparison
This section allows you to compare key financial metrics between Fulcrum Therapeutics, Inc. and MercadoLibre, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities